0001558370-25-010975 | 10-Q | XBRL Viewer

Development Stage Risks and Liquidity (Details) $ in Millions	Jun. 30, 2025 USD ($)
Development Stage Risks and Liquidity
Cash and cash equivalents, and short and long-term investments	$ 254.5

Label	Element	Value
Arrangement, Payments, Milestones	avbp_ArrangementPaymentsMilestones	$ 0
Arrangement, Payments, Milestones	avbp_ArrangementPaymentsMilestones	1,000,000
Research and Development Expense, Product with Specified Ingredient, Other	avbp_ResearchAndDevelopmentExpenseProductWithSpecifiedIngredientOther	6,035,000
Research and Development Expense, Product with Specified Ingredient, Other	avbp_ResearchAndDevelopmentExpenseProductWithSpecifiedIngredientOther	1,569,000
Arrangement, Maximum Payment, Statement of Work	avbp_ArrangementMaximumPaymentStatementOfWork	3,100,000
Arrangement Maximum Payment Near Term Milestones	avbp_ArrangementMaximumPaymentNearTermMilestones	6,000,000
Accrued Research And Development, Current	avbp_AccruedResearchAndDevelopmentCurrent	11,814,000
Accrued Research And Development, Current	avbp_AccruedResearchAndDevelopmentCurrent	8,626,000
Research and Development Expense, Product with Specified Ingredient	avbp_ResearchAndDevelopmentExpenseProductWithSpecifiedIngredient	5,443,000
Research and Development Expense, Product with Specified Ingredient	avbp_ResearchAndDevelopmentExpenseProductWithSpecifiedIngredient	7,334,000
Research and Development Expense, Product with Specified Ingredient	avbp_ResearchAndDevelopmentExpenseProductWithSpecifiedIngredient	19,235,000
Research and Development Expense, Product with Specified Ingredient	avbp_ResearchAndDevelopmentExpenseProductWithSpecifiedIngredient	15,300,000
Research and Development Expense, Product with Specified Ingredient	avbp_ResearchAndDevelopmentExpenseProductWithSpecifiedIngredient	73,000
Research and Development Expense, Product with Specified Ingredient	avbp_ResearchAndDevelopmentExpenseProductWithSpecifiedIngredient	30,000
Research and Development Expense, Cost Reimbursements	avbp_ResearchAndDevelopmentExpenseCostReimbursements	100,000
Arrangement, Maximum Payment, Commercial Milestones	avbp_ArrangementMaximumPaymentCommercialMilestones	655,000,000
Arrangement, Maximum Payment, Commercial Milestones	avbp_ArrangementMaximumPaymentCommercialMilestones	414,000,000
Arrangement, Maximum Payment, Commercial Milestones	avbp_ArrangementMaximumPaymentCommercialMilestones	890,000,000
Prepaid Professional Fees	avbp_PrepaidProfessionalFees	130,000
Prepaid Professional Fees	avbp_PrepaidProfessionalFees	233,000
Proceeds from Issuance Initial Public Offering Or At The Market Offering, Net	avbp_ProceedsFromIssuanceInitialPublicOfferingOrAtMarketOfferingNet	81,857,000
Proceeds from Issuance Initial Public Offering Or At The Market Offering, Net	avbp_ProceedsFromIssuanceInitialPublicOfferingOrAtMarketOfferingNet	185,950,000
Securities Offering, Remaining Authorized, Amount	avbp_SecuritiesOfferingRemainingAuthorizedAmount	164,900,000
Research and Development Expense, Personnel Related and Other Internal Costs	avbp_ResearchAndDevelopmentExpensePersonnelRelatedAndOtherInternalCosts	13,617,000
Research and Development Expense, Personnel Related and Other Internal Costs	avbp_ResearchAndDevelopmentExpensePersonnelRelatedAndOtherInternalCosts	7,906,000
Arrangement, Option to License and Acquire Intellectual Property, Payment	avbp_ArrangementOptionToLicenseAndAcquireIntellectualPropertyPayment	$ 1,000,000
Temporary Equity, Shares, Conversion to Common Stock	avbp_TemporaryEquitySharesConversionToCommonStock	150,000,000
Temporary Equity, Shares, Conversion to Common Stock	avbp_TemporaryEquitySharesConversionToCommonStock	147,619,034
General and Administrative Expense, Personnel Related Costs	avbp_GeneralAndAdministrativeExpensePersonnelRelatedCosts	$ 6,792,000
General and Administrative Expense, Personnel Related Costs	avbp_GeneralAndAdministrativeExpensePersonnelRelatedCosts	4,004,000
Temporary Equity, Value, Conversion to Common Stock	avbp_TemporaryEquityValueConversionToCommonStock	149,865,000
Temporary Equity, Value, Conversion to Common Stock	avbp_TemporaryEquityValueConversionToCommonStock	154,625,000
Arrangement, Cost Reimbursement Received	avbp_ArrangementCostReimbursementReceived	600,000
Arrangement, Cost Reimbursement Received	avbp_ArrangementCostReimbursementReceived	400,000
Prepaid Research and Development	avbp_PrepaidResearchAndDevelopment	13,170,000
Prepaid Research and Development	avbp_PrepaidResearchAndDevelopment	7,209,000
Arrangement, Maximum Payment, Development And Regulatory Milestones	avbp_ArrangementMaximumPaymentDevelopmentAndRegulatoryMilestones	201,500,000
Arrangement, Maximum Payment, Development And Regulatory Milestones	avbp_ArrangementMaximumPaymentDevelopmentAndRegulatoryMilestones	$ 300,000,000
Stock Issued During Period, Shares, Issued in Execution of Agreement	avbp_StockIssuedDuringPeriodSharesIssuedInExecutionOfAgreement	1,276,250
Arrangement, Maximum Payment Per Product, Clinical And Regulatory Milestones	avbp_ArrangementMaximumPaymentPerProductClinicalAndRegulatoryMilestones	$ 18,000,000
Tax Credit Receivable, Current	avbp_TaxCreditReceivableCurrent	505,000
Tax Credit Receivable, Current	avbp_TaxCreditReceivableCurrent	500,000
Arrangement, Initiation Fee	avbp_ArrangementInitiationFee	$ 300,000
Class of Warrant or Right, Exercised During Period	avbp_ClassOfWarrantOrRightExercisedDuringPeriod	0
Securities Offering, Authorized, Amount	avbp_SecuritiesOfferingAuthorizedAmount	$ 250,000,000
Proceeds From Public Offering, Net Of Commission	avbp_ProceedsFromPublicOfferingNetOfCommission	81,100,000
Arrangement, Initiation and Research Fees, Payment	avbp_ArrangementInitiationAndResearchFeesPayment	5,200,000
Research and Development Expense, Discovery Stage Programs	avbp_ResearchAndDevelopmentExpenseDiscoveryStagePrograms	44,606,000
Research and Development Expense, Discovery Stage Programs	avbp_ResearchAndDevelopmentExpenseDiscoveryStagePrograms	6,614,000
Proceeds from At The Market Offering, Net	avbp_ProceedsFromAtMarketOfferingNet	81,900,000
Research and Development Expense, Approval of Target Pair Selection	avbp_ResearchAndDevelopmentExpenseApprovalOfTargetPairSelection	$ 1,200,000
Threshold Notice Period, Exercise of Warrants Exceeding Specified Limit	avbp_ThresholdNoticePeriodExerciseOfWarrantsExceedingSpecifiedLimit	61 days
Deferred Offering Costs Transferred to Additional Paid in Capital	avbp_DeferredOfferingCostsTransferredToAdditionalPaidInCapital	$ 2,733,000
Proceeds from Issuance Initial Public Offering, Net	avbp_ProceedsFromIssuanceInitialPublicOfferingNet	183,200,000
Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Two Years, Fair Value	avbp_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateRollingAfterOneThroughTwoYearsFairValue	18,800,000
Arrangement, Non Refundable Cash Payment	avbp_ArrangementNonRefundableCashPayment	40,000,000
Arrangement, Non Refundable Cash Payment	avbp_ArrangementNonRefundableCashPayment	40,000,000
Arrangement, Maximum Payment Per Product, Commercial Milestones	avbp_ArrangementMaximumPaymentPerProductCommercialMilestones	80,000,000
Arrangement, Maximum Payment, Clinical And Regulatory Milestones	avbp_ArrangementMaximumPaymentClinicalAndRegulatoryMilestones	$ 105,000,000

Print Document
Details Development Stage Risks and Liquidity (Details) Uncategorized Uncategorized Items - avbp-20250630x10q_htm.xml All Reports